Copyright Reports & Markets. All rights reserved.

Global Live and Attenuated Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Live and Attenuated Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Pediatric Vaccine
    • 1.3.3 Adult Vaccines
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Live and Attenuated Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospitals
    • 1.4.3 Clinics
    • 1.4.4 Diagnostic Centers
    • 1.4.5 Research Institute
    • 1.4.6 Others
  • 1.5 Global Live and Attenuated Vaccine Market Size & Forecast
    • 1.5.1 Global Live and Attenuated Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Live and Attenuated Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global Live and Attenuated Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 GlaxoSmithKline
    • 2.1.1 GlaxoSmithKline Details
    • 2.1.2 GlaxoSmithKline Major Business
    • 2.1.3 GlaxoSmithKline Live and Attenuated Vaccine Product and Services
    • 2.1.4 GlaxoSmithKline Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 GlaxoSmithKline Recent Developments/Updates
  • 2.2 Merck & Co.
    • 2.2.1 Merck & Co. Details
    • 2.2.2 Merck & Co. Major Business
    • 2.2.3 Merck & Co. Live and Attenuated Vaccine Product and Services
    • 2.2.4 Merck & Co. Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Merck & Co. Recent Developments/Updates
  • 2.3 Pfizer, Inc
    • 2.3.1 Pfizer, Inc Details
    • 2.3.2 Pfizer, Inc Major Business
    • 2.3.3 Pfizer, Inc Live and Attenuated Vaccine Product and Services
    • 2.3.4 Pfizer, Inc Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Pfizer, Inc Recent Developments/Updates
  • 2.4 Astellas Pharma Inc
    • 2.4.1 Astellas Pharma Inc Details
    • 2.4.2 Astellas Pharma Inc Major Business
    • 2.4.3 Astellas Pharma Inc Live and Attenuated Vaccine Product and Services
    • 2.4.4 Astellas Pharma Inc Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Astellas Pharma Inc Recent Developments/Updates
  • 2.5 Johnson & Johnson
    • 2.5.1 Johnson & Johnson Details
    • 2.5.2 Johnson & Johnson Major Business
    • 2.5.3 Johnson & Johnson Live and Attenuated Vaccine Product and Services
    • 2.5.4 Johnson & Johnson Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Johnson & Johnson Recent Developments/Updates
  • 2.6 CSL Limited
    • 2.6.1 CSL Limited Details
    • 2.6.2 CSL Limited Major Business
    • 2.6.3 CSL Limited Live and Attenuated Vaccine Product and Services
    • 2.6.4 CSL Limited Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 CSL Limited Recent Developments/Updates
  • 2.7 Emergent BioSolutions, Inc.
    • 2.7.1 Emergent BioSolutions, Inc. Details
    • 2.7.2 Emergent BioSolutions, Inc. Major Business
    • 2.7.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product and Services
    • 2.7.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Emergent BioSolutions, Inc. Recent Developments/Updates
  • 2.8 MedImmune, LLC
    • 2.8.1 MedImmune, LLC Details
    • 2.8.2 MedImmune, LLC Major Business
    • 2.8.3 MedImmune, LLC Live and Attenuated Vaccine Product and Services
    • 2.8.4 MedImmune, LLC Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 MedImmune, LLC Recent Developments/Updates
  • 2.9 Sanofi
    • 2.9.1 Sanofi Details
    • 2.9.2 Sanofi Major Business
    • 2.9.3 Sanofi Live and Attenuated Vaccine Product and Services
    • 2.9.4 Sanofi Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Sanofi Recent Developments/Updates
  • 2.10 Serum Institute
    • 2.10.1 Serum Institute Details
    • 2.10.2 Serum Institute Major Business
    • 2.10.3 Serum Institute Live and Attenuated Vaccine Product and Services
    • 2.10.4 Serum Institute Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Serum Institute Recent Developments/Updates

3 Competitive Environment: Live and Attenuated Vaccine by Manufacturer

  • 3.1 Global Live and Attenuated Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Live and Attenuated Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Live and Attenuated Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Live and Attenuated Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Live and Attenuated Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Live and Attenuated Vaccine Manufacturer Market Share in 2025
  • 3.5 Live and Attenuated Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Live and Attenuated Vaccine Market: Region Footprint
    • 3.5.2 Live and Attenuated Vaccine Market: Company Product Type Footprint
    • 3.5.3 Live and Attenuated Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Live and Attenuated Vaccine Market Size by Region
    • 4.1.1 Global Live and Attenuated Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Live and Attenuated Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Live and Attenuated Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Live and Attenuated Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Live and Attenuated Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Live and Attenuated Vaccine Consumption Value (2021-2032)
  • 4.5 South America Live and Attenuated Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Live and Attenuated Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Live and Attenuated Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Live and Attenuated Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Live and Attenuated Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Live and Attenuated Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Live and Attenuated Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Live and Attenuated Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Live and Attenuated Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Live and Attenuated Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Live and Attenuated Vaccine Market Size by Country
    • 7.3.1 North America Live and Attenuated Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Live and Attenuated Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Live and Attenuated Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Live and Attenuated Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Live and Attenuated Vaccine Market Size by Country
    • 8.3.1 Europe Live and Attenuated Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Live and Attenuated Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Live and Attenuated Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Live and Attenuated Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Live and Attenuated Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Live and Attenuated Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Live and Attenuated Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Live and Attenuated Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Live and Attenuated Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Live and Attenuated Vaccine Market Size by Country
    • 10.3.1 South America Live and Attenuated Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Live and Attenuated Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Live and Attenuated Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Live and Attenuated Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Live and Attenuated Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Live and Attenuated Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Live and Attenuated Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Live and Attenuated Vaccine Market Drivers
  • 12.2 Live and Attenuated Vaccine Market Restraints
  • 12.3 Live and Attenuated Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Live and Attenuated Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Live and Attenuated Vaccine
  • 13.3 Live and Attenuated Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Live and Attenuated Vaccine Typical Distributors
  • 14.3 Live and Attenuated Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Live and Attenuated Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global Live and Attenuated Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Live and Attenuated Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Live and Attenuated Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Live and Attenuated Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Live and Attenuated Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Live and Attenuated Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Live and Attenuated Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GlaxoSmithKline, Merck & Co., Pfizer, Inc, Astellas Pharma Inc, Johnson & Johnson, CSL Limited, Emergent BioSolutions, Inc., MedImmune, LLC, Sanofi, Serum Institute, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Live and Attenuated Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Pediatric Vaccine
    Adult Vaccines
    Market segment by Application
    Hospitals
    Clinics
    Diagnostic Centers
    Research Institute
    Others
    Major players covered
    GlaxoSmithKline
    Merck & Co.
    Pfizer, Inc
    Astellas Pharma Inc
    Johnson & Johnson
    CSL Limited
    Emergent BioSolutions, Inc.
    MedImmune, LLC
    Sanofi
    Serum Institute
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Live and Attenuated Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Live and Attenuated Vaccine, with price, sales quantity, revenue, and global market share of Live and Attenuated Vaccine from 2021 to 2026.
    Chapter 3, the Live and Attenuated Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Live and Attenuated Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Live and Attenuated Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Live and Attenuated Vaccine.
    Chapter 14 and 15, to describe Live and Attenuated Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now